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1INTRODUCTION
Before the early 20th century, tracheal intubation was done for
conditions including tumors of the oral cavity and obstruction in the
larynx. It was done crudely using fingers as a makeshift laryngoscope and
without using any drugs. In 1909, ether anesthesia was introduced for the
purpose of tracheal insufflations. In 1913, Rowbotham modified the
technique and described a series of cases. These tracheal tubes were wide
bore catheters and forceps was used to guide them into the trachea.
Before the development of neuromuscular blocking agents,
endotracheal intubation was done under deep inhalational anaesthesia
with ether. Following this, halothane was used to facilitate tracheal
intubation.  Nowadays, sevoflurane is the most commonly used drug for
inhalational induction in peadiateric age group. In 1942, neuromuscular
blocking drugs were first introduced into clinical practice  to facilitate
tracheal intubation.
In 1948 Lewis et al used thiopentone sodium for tracheal
intubation without using neuromuscular blocking drugs. His study
showed that adequate intubating conditions were achieved using
thiopentone sodium alone. Tracheal intubation is usually done with
muscle relaxants  supplemented  with induction agents. Over the past few
years, several factors have led the researchers to consider omitting
2neuromuscular blocking agents for tracheal intubation. Endotracheal
intubation was facilitated by the apparent ability of propofol to blunt
responses to tracheal stimulation and the availability of the short acting
opioids, remifentanil and alfentanil.
Tracheal Intubation without the use of neuromuscular blocking
drugs were used to assess the airway by laryngoscopy and to ascertain if
oxygenation is possible. This technique may be useful in both predicted
and unexpected difficult intubation and also in cases where
neuromuscular blocking agents are either contraindicated or not required.
The  side effects of succinylcholine, and also those of non-depolarizing
drugs, such as anaphylaxis are avoided.
Laryngoscopy and endotracheal intubation are mandatory for most
patients undergoing general anaesthesia, which is invariably associated
with certain cardiovascular changes such as tachycardia or bradycardia,
rise in blood pressure and a wide variety of cardiac arrhythmias. These
effects are deleterious in susceptible individuals culminating in
perioperative myocardial ischemia, acute heart failure and
cerebrovascular accidents. The cardiovascular response to laryngoscopy
and endotracheal intubation has been recognized since 1951. The
response following laryngoscopy and intubation peaks at 1-2 minutes and
returns to normal within 5-10 minutes.
Though these sympatho adrenal responses are probably of little
consequence in healthy individuals, it is hazardous to those patients with
3hypertension, coronary heart disease, intra cranial pathology and hyper
reactive airways.
Various systemic as well as topical agents were used to reduce
these untoward hemodynamic responses due to laryngoscopy and
intubation. The common strategies adopted are narcotics, vasodilators,
beta blockers, calcium channel blockers, lidocaine and other
sympatholytics.
After the emergence of shorter-acting opioids like remifentanil and
alfentanil, these drugs were combined with propofol for successful
tracheal intubation without muscle relaxants. These  drugs are not yet
available in many developing countries. Fentanyl is the opioid commonly
available and being used in combination with propofol, lignocaine and
midazolam for intubation without muscle relaxants.
4ANATOMY OF LARYNX
 It is a protective sphincter of the respiratory tract and it contains
the vocal cords. It contains muscles of the larynx, cartilages, ligaments
and membranes. It extends from C3 - C6 cervical vertebrae.
Measurements of the larynx include:
TABLE.I
Parameters Males Females
Length 44 mm. 36 mm.
Transverse diameter 43 mm. 41 mm.
Antero-posterior
diameter
36 mm. 26 mm.
Circumference 136 mm. 112 mm
RELATIONS
Anteriorly - covered by the fascia, platysma and skin
Posteriorly - pharynx, prevertebral muscles and cervical vertebrae
Superiorly - pharyngeal structures
Inferiorly - continues as trachea
5Cartilages of the Larynx
 There are nine cartilages in the larynx, three of which are paired
and three are unpaired.
TABLE.II
Unpaired cartilages Paired cartilages
Thyroid Two Arytenoid
Cricoid Two Corniculate
Epiglottis Two Cuneiform
? Epiglottis: Leaf like structure, the lower part of the epiglottis is
attached to the thyroid cartilage by the thyro-epiglottic ligament,
and the upper broader is free to project superiorly. Its posterior free
surface forms a bulge called the tubercle. Valleculae are the region
between the medial and lateral glosso- epiglottic fold and it is the
most common site of fish bone impaction.
? Thyroid cartilage: Sheild like shape , the lower part of its two
laminae join together to form a prominence in the males called
Adam’s apple; it is less prominent in females. It is the largest
laryngeal cartilage and inferiorly it articulates with cricoid
cartilage.
6? Cricoid cartilage (hyaline): ‘signet ring’ shaped and it is situated
at the level of C6 vertebrae. The lateral border articulates with the
thyroid cornua, and on its upper border with the arytenoid
cartilages.
? Arytenoid cartilages:  Pyramidal in shape, each with a lateral
muscular process (for insertion of both crico-arytenoid muscles)
and an anterior vocal process (for the posterior attachment of the
vocal ligament).
? Corniculate cartilages: present  on  the  apex  of  the  arytenoid
cartilage.
?  Cuneiform cartilages:  It is a flake of cartilage within the margin
  of the ary-epigloltic fold.
LIGAMENTS
   There are four extrinsic and intrinsic ligaments in the larynx.
? Thyrohyoid membrane: It stretches between the upper border of
the thyroid and the hyoid bone.
? Hyo-epiglottic ligament: It connects the  epiglottis to the back of
the body of the hyoid
? Cricothyroid ligament: Lies between the thyroid cartilage and the
cricoid cartilage, it is the preferred site for cricothyrotomy.
?  Cricotracheal ligament: which links the cricoid cartilage to the
  first tracheal ring.
7MUSCLES OF THE LARYNX
Extrinsic:
? Sternothyroid -   depresses the larynx
? Thyrohyoid -  elevates the larynx
? Inferior constrictor -  constrictors of the pharynx
Intrinsic:
?  Posterior crico-arytenoid –abducts the cord by external rotation of
the Arytenoids.
? Lateral crico-arytenoid –adducts the cord by internal rotation of the
Arytenoids.
? Inter arytenoid – closes the posterior part of the glottis
? Thyro-arytenoid – relaxes the cords by shortening the cords.
? Vocalis – fine adjustment of vocal cord tension
? Cricothyroid – tensor of the vocal cords
BLOOD SUPPLY
1. Arterial supply
?  Superior laryngeal artery is a branch of superior thyroid artery;
It runs with the internal branch of the superior laryngeal nerve
?  Inferior laryngeal artery is a branch of the inferior thyroid artery,
It accompanies the recurrent laryngeal nerve.
82. Venous drainage through the corresponding superior and inferior
thyroid veins
Nerve Supply of Larynx
Vague is the main nerve supply of the larynx, divided into superior
laryngeal nerve and recurrent laryngeal nerve.
The Superior Laryngeal nerve arises from the inferior ganglion of
Vagus. It is further divided in to external and internal branches. The
external branch provides motor supply to the cricothyroid muscle while
the internal branch divides into two main sensory and secretomotor
branches.
The upper branch supplies the mucous membrane of lower part of
phaynx, epiglottis, vallecula and vestibule of larynx. The lower branch
supplies the aryepiglottic fold and mucous membrane down to the level
of vocal folds.
The Internal branch of superior laryngeal nerve supplies the
mucosa above the level of glottis.
The Recurrent laryngeal nerve ascends to the larynx in the groove
between the oesophagus and trachea and divides into motor and sensory
branches.
The motor branch supplies all the intrinsic muscles of larynx
except the cricothyroid.
The sensory branch supplies the laryngeal mucous membrane
below the level of vocal folds.
9LARYNGOSCOPIC ANATOMY
Oral, pharyngeal and laryngeal axis should be in the same plane for
laryngoscopy and intubation.
During direct laryngoscopy the following structures are seen in the
order: the base of the tongue, the valleculae, the anterior surface of the
epiglottis and the aryepiglottic folds containing cuneiform and corniculate
cartilages.
The vocal cords appear as pale, glistening structure that extends
from the angle of the thyroid cartilage to the vocal processes of the
arytenoids. Between the vocal cords the triangular opening is called
rimaglottidis, through which the upper two or three tracheal rings can be
visualized.
LARYNGOSCOPIC ANATOMY
10
                                   LARYNGEAL AXIS
In supine position the oral, pharyngeal and laryngeal axes of the
patient are offset, making it difficult to obtain a good view of the glottis
by the conventional laryngoscope. Flexion of neck (25 to 35 degree)
causes alignment of pharyngeal and laryngeal axis in the same plane.
Then subsequent head extension at the atlanto occipital joint (80 to 85
degree) causes alignment of oral axis with the pharyngeal and
subsequently with the laryngeal axis. This position (neck flexion and
head extension) is called optimal sniffing position.
In  adults,  a  head  elevation  of  8  –  10  cm,  as  on  a  pillow  or
doughnut, achieves appropriate neck flexion. No such head elevation is
required in pediatric age group as their large head circumference size
produces neck flexion as the head is extended at atlanto-occipital joint.
The sniffing position has been recommended as the optimal one for
intubation and airway management. Historically, the definition of this
position is credited to an Irish born anaesthetist, Sir Ivan Magill (1936),
who described it as “sniffing the morning air” or “draining a pint of
beer”.
Banister and Macbeth described the technique and they analysed
the angles of the oral, pharyngeal, and laryngeal axes with the head in
different positions for the purpose of identifying the best possible
alignment of the three axes to expose the glottis and facilitate
endotracheal tube insertion.
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The key components are flexion of the lower cervical spine,
extension of the upper cervical spine and atlanto-occipital joint.
The main advantage of this position is the optimal exposure of the
glottis for the purpose of intubation. The disadvantage include its
inadequacy in obese patients to optimize glottis exposure by direct
laryngoscopy. It is contraindicated in patients with known or suspected
cervical injuries.
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MALLAMPATTI CLASSIFICATION
This is probably the most commonly employed test for predicting
difficult airway. It indicates the amount of space within the oral cavity to
accommodate the laryngoscope and ETT. Performing the test
meticulously is critical to correct prediction. This is performed by having
the patient open the mouth as wide as possible and stick out the tongue
without phonation. One should also ensure that the patient is in the sitting
position with the head protruding forward, mimicking the “sniffing”
position of laryngoscopy and intubation. The observer’s eye should be at
level of the patient’s open mouth so that the faucial pillars, uvula, soft
palate and the hard palate are visible. As per Samsoon and Young’s
modification of Mallampati grading, following 4 grades may be noted :
Grade I :  Faucial pillars, uvula, soft and hard palate visible.
Grade II :  Uvula, soft and hard palate visible.
Grade III : Base of uvula or none, soft and hard palate visible.
Garde IV : Only hard palate visible.
Grade I and II are associated with easy laryngoscopic view of the
glottis.Grade III and IV implies difficult viewing of the glottis by
conventional laryngoscopy.
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CORMACK AND LEHANE GRADING OF LARYNGOSCOPIC
VIEW
Grade I : Visualization of entire vocal cords.
Grade II : Visualization of posterior part of vocal cord.
Grade III : Vsualization of epiglottis.
Grade IV : No glottic structures seen.
Cook (1999) has further subdivided Cormack and Lehane’s Grade
II and III into IIa, IIb, IIIa, and IIIb. II a and II b indicates visualization of
posterior part of vocal cord and tip of the arytenoids respectively.III a
indicates liftable epiglottis and III b indicates adherent epiglottis. As per
Cook, grade I and IIa patient can be directly intubated, IIb and IIIa would
require bougie while IIIb and IV cannot be intubated using conventional
laryngoscope and bougie, but would require alternative specialized
techniques.
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PATHOPHYSIOLOGY OF LARYNGOSCOPY AND
INTUBATION RESPONSE
PATHOPHYSIOLOGY OF CARDIOVASCULAR CHANGES
DURING LARYNGOSCOPY AND ENDOTRACHEAL
INTUBATION
Tracheal intubation alters the respiratory and cardiovascular
physiology by both reflex response and by physical presence of
endotracheal tube. Although reflex responses are generally of short
duration and of little consequence in majority of patients, they may
produce profound disturbances in patients with underlying abnormalities
such as hypertension, coronary heart disease, reactive airways, and
intracranial pathology.
CARDIOVASCULAR RESPONSE
The common cardiovascular responses to laryngoscopy and
endotracheal intubation are increased blood pressure and heart rate,
mediated by the cardio accelerator nerves (sympathetic efferent) and
sympathetic chain ganglia. This autonomic response following
endotracheal intubation is due to release of norepinephrine from
adrenergic nerve terminals and adrenal medulla.
Increased blood pressure following intubation results from the
activation of renin angiotensin system. Its activation releases the renin
from the renal juxta glomerular apparatus of the kidney innervated by
beta adrenergic nerve terminals.
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The effects of endotracheal intubation on the pulmonary
vasculature are less well understood than the responses elicited in the
systemic circulation. They are often coupled with the changes in airway
reactivity associated with intubation. They are i) glottis closure reflex
(laryngospasm due to brisk motor response, ii) decrease in dead space, iii)
increase in airway resistance, iv) bronchospasm (a reflex response to
intubation), v) removal of glottis barrier and  reduction in lung volume,
vi)  reduction of efficiency of cough reflex.
Methods used to decrease cardiovascular responses to laryngoscopy
and intubation.
To reduce the risk of peri operative ischemia and infarction the
balance between the myocardial oxygen supply and demand should be
maintained.
Factors affecting myocardial oxygen demand and supply:
Demand
? Basal requirement
? Heart rate
? Wall tension-preload, after load
? Contractility
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Supply
? Heart rate – depends on diastolic time. Increases in heart rate
shorten diastolic time, resulting in decreased oxygen supply
to myocardium.
? Coronary Perfusion Pressure –CPP increases with high aortic
diastolic pressure and low ventricular end diastolic pressure.
? Arterial oxygen content – depends on arterial oxygen partial
pressure and haemoglobin concentration.
? Coronary vessel diameter.
Increasing depth of General Anaesthesia
Inhalational agents are used to blunt the cardiovascular responses
during laryngoscopy and endotracheal intubation. This is achieved by
increasing the concentration of inhalational agents resulting in profound
cardiovascular depression prior to laryngoscopy and intubation. Various
agents used are Halothane, Isoflurane, and Sevoflurane.
1. Lidocaine
? Lidocaine gargle for oropharyngeal anaesthesia.
? Aerosol for intra-tracheal anaesthesia
? Topical spray for vocal cords
? Regional nerve blocks - Superior Laryngeal nerve,
Glossopharyngeal nerve
? Intra venous bolus of systemic anaesthesia.
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Mechanism of action of Intravenous lignocaine
? By Increasing the depth of General Anaesthesia
? Potentiation of effects of nitrous Oxide and reduction of
MAC of   Halothane by 10-28%
? Direct Cardiac depressant
? Peripheral Vasodilation
? Antiarrhythmic properties
? Suppression of cough reflex.
2. Vasodilators
? Hydralazine : Bolus: 5-20 mg, infusion 0.25 -1.5
µg/kg/min
? Sodium nitroprusside: Bolus:50-100 µg, infusion 0.5-10
µg/kg/min
? Nitroglycerine: Bolus: 50-100 µg, infusion 0.5-10
 µg/kg/min
3. Narcotics
? Fentanyl       - 2µg/kg,
? Alfentanil     - 20µg/kg,
? Remifentanil - 2µg/kg
Mechanism of action of opioids
? Suppression of Nociceptive Stimulation caused by
Intubation
? Centrally mediated decrease in sympathetic tone
? Activation of vagal tone.
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4. Adrenergic blockers
? Long acting - Metoprolol  1- 15 mg,
Propronalol 1- 10 mg.
? Short acting - Esmolol 0.5mg/kg followed by
50-200µg/kg/min.
5. Alpha2 agonist – Clonidine.
6. Midazolam – Sedative & Anxiolytic
7. MagnesiumSulphate – Sedative & Anxiolytic.
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PHARMACOLOGY OF PROPOFOL21
CHEMICAL STRUCTURE
Chemical name is 2,6-di-isopropylphenol
COMMERCIAL PREPARATION
It is a white oil-in-water emulsion, it contains
1% - propofol
10% - soyabean oil
2.25% - glycerol
1.25% - purified egg phosphatide with a pH -7.
MECHANISM OF ACTION
It is a selective modulator of GABA–A receptor, acts by increasing
the transmembrane Cl- conductance resulting in hyperpolarization.
It also reduces the dissociation of GABA from its receptors
leading, to increase in the duration of Cl- channel opening.
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PHARMACOKINETICS
Volume of distribution (L/kg) : 3.5 – 4.5
Context sensitive t1/2(min) : 40
Elimination t1/2(hrs) : 0.5 -1.5
Clearance (ml/kg/min)                     : 30-60
CLINICAL USES
Propofol is the induction agent of choice, where conditions
required rapid and complete awakening after anaesthesia.
INDUCTION OF ANAESTHESIA
Dose: 1.5-2.5mg/kg IV Higher dose required in children. Elderly
patients require lower doses. Complete awakening without residual CNS
effects is the characteristic feature of Propofol.
INTRAVENOUS SEDATION
Dose : 25-100 µg/kg/min, Fast recovery without residual effect.
Used as a sedative during mechanical ventilation in ICU.
Provides control of stress responses and has anticonvulsant and
amnestic properties.
MAINTENANCE OF ANAESTHESIA
Dose : 100-300 µg/kg/min, in combination with opioids or
midazolam used in short ambulatory procedures. Minimal postoperative
nausea and vomiting.
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NON HYPNOTIC THERAPEUTIC APPLICATIONS
ANTI EMETIC EFFECTS
Dose : 10-15mg IV, sub hypnotic dose. Used in post anaesthesia
care unit to treat nausea and vomiting, chemotherapy induced nausea and
vomiting.
ANTI PRURITIC EFFECTS
Dose  :  10  mg  IV,  Used  in  treatment  of  pruritus  associated  with
opioids and cholestasis.
ANTI CONVULSANT ACTIVITY
Acts by GABA-mediated presynaptic and post synaptic inhibiton
of cl- channels.
ATTENUATION OF BRONCHOCONSTRICTION
Reduces the incidence of wheezing after induction and
endotracheal intubation both in healthy and asthmatic patients.
EFFECTS ON ORGAN SYSTEMS
CENTRAL NERVOUS SYSTEM
 It decreases the cerebral metabolic rate for oxygen (CMRO2),
cerebral blood flow and intracranial pressure (ICP).Cerebral
autoregulation and cerebral blood flow to changes to Paco2 are not
affected. Higher doses produce burst suppression in EEG.
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CARDIOVASCULAR SYSTEM
It reduces the blood pressure and heart rate. These effects are
increased in elderly, coronary heart disease and hypovolemic patients.
Heart rate responses to intravenous atropine are attenuated in patients
receiving propofol, due to suppression of sympathetic nervous system
activity. Treatment for propofol induced bradycardia is ?-agonist
Isoproterenol.
LUNGS
Produces dose dependent depression of ventilation in 25%-35%
patients. Preoperative medication like opioids may enhance this
ventilatory depressant effects. Produces bronchodilation and decreases
the incidence of intra operative wheezing in asthmatic patients.
HEPATIC AND RENAL FUNCTION
No significant adverse effects.
INTRAOCULAR PRESSURE
Decreases intraocular pressure after induction and intubation.
SIDE EFFECTS
Allergic Reactions
Allergic components include phenyl nucleus and diisopropyl side
chain.
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Lactic Acidosis
Also known as propofol infusion syndrome. Occurs in patients
receiving high dose infusions 75µg/kg/min for 24hrs. Unexplained
tachycardia during anaesthesia should raise the suspicion of metabolic
acidosis. Laboratory evaluation includes arterial blood gases and serum
lactate. It is reversible in early stage with the discontinuation of drug.
PROCONVULSANT ACTIVITY
Due to spontaneous excitatory movements of subcortical origin.
Prolonged myoclonus associated with meningismus.
BACTERIAL GROWTH
It supports the growth of E.coli and Psedomonas aeruginosa.
Aseptic technique should be used while handling. Contents should be
used within 6hrs after opening of the vial.
INJECTION PAIN
Injection pain is reduced by prior administration of 1% lignocaine
or a short acting opioid.
ANTI OXIDANT PROPERTIES
Similar to vitamin E
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PHARMACOLOGY OF FENTANYL22
CHEMICAL STRUCTURE
Fentanyl is synthetic phenylpiperidine opioid of the 4-
anilopiperidine series which is structurally related to pethidine.
COMMERCIAL PREPARATION
Commercially fentanyl is formulated as a citrate, available as an
aqueous solution without preservatives. Each ml contains a base of 50?g
of fentanyl citrate.
PHARMACOKINETIC PROFILE
Molecular Weight : 528.29
Pka :  8.4
Unionized form in pH 7.4 :  8.5
Octanol / water partition coefficient :  816
Bound to plasma proteins (Percentage) :  84
Potency :  80 times more potent
   than morphine
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Pharmacodynamics
Analgesia
This results from action of fentanyl on opioid ? receptors both
supra spinally in the brain and in the spinal cord. Intravenous fentanyl
produces effective analgesia at plasma concentrations between 0.6-
3.0ng/ml.
Cardiovascular system
Arterial blood pressure, cardiac output and pulmonary vascular
resistance remain unchanged after large doses of intravenous fentanyl.
Fentanyl like other opioid agonists (expect pethidine) causes bradycardia
that responds to intravenous atropine. Peripheral vasodilation is much less
than morphine due to absence of histamine release.
Respiratory System
Fentanyl causes a direct dose related respiratory depression by its
depressant effect on the medullary respiratory center, manifested as a
decreased sensitivity to carbondioxide and reduced respiratory rate. It is
reversed by intravenous Naloxone administration. Fentanyl
concentrations in the plasma >2ng/ml is associated with respiratory
depression. The respiratory depression depends on various factors,
including type of the surgical procedure, age of the patient and individual
pharmacodynamic response.
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Central nervous System
Fentanyl causes less sedation than equianalgesic doses of
morphine. In doses of 100 ?g, fentanyl causes dose related reduction in
cerebral blood flow and CMRO2. Catatonic state due to fentanyl injection
is manifestated as muscle rigidity, due to increased dopamine
biosynthesis in the caudate nucleus.
Gastrointestinal system
Fentanyl decreases gastrointestinal tract motility, increases intra
gastric pressure and causes a varying incidence of nausea and vomiting. It
is due to chemoreceptor trigger zone stimulation in the area postrema.
Genito-urinary System
Fentanyl like other opioids causes relaxation of detrusor muscle
and increase in urethral sphincter tone leading to urinary retention. This is
probably not dose related and is more common with central neuraxial
administration.
Pharmacokinetics
Fentanyl is a potent opioid, highly lipophilic, producing a rapid
onset of action of relatively short duration. After intravenous
administration, it is fastly distributed to Heart, Brain and highly perfused
tissues. It crosses the placental barrier. Peak effect occurs in 5 minutes.
Within  a  short  time,  the  drug  redistributes  to  inactive  tissue  sites  like
skeletal muscle and fat, associated with decrease in plasma concentration
of drug, thus terminating its effect. About 75% of initial dose undergoes
first pass pulmonary uptake.
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When low doses (1-2?g/kg) are administrated, redistribution
terminates the effect and the drug appears short acting. With
administration of large intravenous doses or continous infusion,
progressive saturation of inactive tissue sites occur, with redistribution
becoming insufficient to terminate drug action which becomes dependent
on slow elimination process and the drug appears to be long acting .
Pharmacokinetic profile
Volume of distribution of steady state : 335litres
Clearance : 539 ml/min
Effect-site equilibration time : 6.8min
Hepatic extraction ratio : 0.8-0.1
Context –Sensitive t ½ (4 hrs infusion) : 260 min
Elimination t ½ : 3.1 to 6.6 hours.
Metabolism
Fentanyl is biotransformed in the liver to inactive metabolites,
primarily norfentanyl and several hydroxylation products. Only 4-7 % of
drug is excreted unchanged in urine. Elimination t ½ of fentanyl is longer
than that of morphine because of high lipid solubility of fentanyl.
Elimination t ½ is prolonged in elderly patients. A high hepatic extraction
ratio means that the clearance of fentanyl is limited by hepatic blood
flow.
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Routes of Administration and Dosage
Intramuscular
50 -100?g may be administrated intramuscularly as premedication
30 to 60 minutes prior to surgery.
Intravenous
Can be given intra operatively and for postoperative analgesia.
Postoperative pain relief is given by intravenous bolus dose of 1-2?g/kg
followed by an infusion dose of 1-2?g/kg/hr. In Patient Controlled
Analgesia (PCA) bolus dose is 20-50?g with lockout intervals.
Transdermal
Transdermal fentanyl patch is available in four sizes; it provides
sustained release of fentanyl citrate at rates of 25 ?g/hr, 50 ?g/hr, 75?g/hr
and 100?g/hr over a period of 48-72 hrs. Skin acts as a secondary
reservoir contributing to prolonged residual fentanyl concentrations.
Transmucosal
Oral transmucosal fentanyl citrate contains fentanyl citrate in a
candy shaped into a stick. Time to onset of analgesia is 4minutes and the
duration of analgesia is 150minutes.
Intranasal
It is also administrated with a metered dose device. During   each
spray it delivers 4.5?g fentanyl. Time to onset of analgesia is about 15
minutes.
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Transpulmonary
    Inhalational route of fentanyl administration produces rapid,
effective drug delivery. A dose of 300?g of fentanyl administrated via
oxygen driven nebulizer produces effective postoperative analgesia in 5
min and lasts for about 2 hours.
Clinical Application
Premedication
Fentanyl in doses of 50-100?g may be administrated
intramuscularly 30-60 minutes prior to surgery. Oral transmucoal
fentanyl citrate in doses between 15-20?g/kg, administrated 45 minutes
before surgery produces reliable preoperative sedation and facilities
induction of anaesthesia in children.
Adjunct to general anaesthesia
Fentanyl in doses of 1-2?g given intravenously provides analgesia.
It is used as an adjuvant to decreases the cardiovascular responses that
occur during direct laryngoscopy for intubation and surgical stimulation.
Large doses of fentanyl, 50-150?g/kg intravenously has been used as sole
anesthetic agent especially in cardiothoracic procedures, principally
because of its stable hemodynamic effects.
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Neruolept analgesia
It is a premixed combination, containing 2.5mg Droperidol and
0.05mg Fentanyl in each ml (50:1) used for neuroplept analgesia and
anaesthesia.
Adjunct in Central neuraxial Block
Fentanyl added to local anesthetic either intrathecally or epidurally,
improves the quality of intraoperative analgesia and also provides good
post operative analgesia.
Postoperative analgesia
Fentanyl administration by intravenous, epidural, intrathecal and
transdermal routes provides effective postoperative analgesia. Newer
routes like intranasal and inhalational administration are being evaluated
as minimally invasive means of postoperative analgesia.
Side effects
Commonly occurring side effects include dose dependent
respiratory depression, nausea and vomiting, pruritus, urinary retention
and bradycardia. These effects are reversed by administration of
Naloxone intravenously.
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PHARMACOLOGY OF MIDAZOLAM23
CHEMICAL STRUCTURE
Midazolam belongs to Benzodiazepine group. The imidazole ring
in the structure of the midazolam is responsible for its stability in aqueous
solutions and its rapid metabolism. Amnestic effects of midazolam is
more potent than its sedative properties. It is 2-3times more potent than
diazepam. After its administration patient may be awake but remain
amnestic for events and conversations for several hours.
COMMERCIAL PREPARATION
Available as an aqueous solution with solubilizing preparation like
propylene glycol. It is compatible with acidic salts of drugs like opioids,
anticholinergics and Ringer lactate.
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PHARMACOKINETICS
TABLE.III
Volume of distribution  (L/kg) 1-1.5
Protein Binding (%) 96-98
Clearance  (ml/kg/min) 6-8
Elimination t1/2(hrs) 1-4
Effect site equilibration time  (min) 0.9-5.6
METABOLISM
It is metabolized by hepatic and small intestinal enzymes CYP450
(CYP3A4). The metabolism is slowed by CYP450 inhibitors like
cimetidine, erythromycin, calcium channel blockers and antifungals. Its
active metabolite is 1-OH midazolam.
RENAL CLEARANCE
Pharmacokinetic property is not altered by renal failure.
EFFECTS ON ORGAN SYSTEMS
CENTRAL NERVOUS SYSTEM
It reduces the cerebral metabolic oxygen requirement (CMRO2)
and cerebral blood flow. It is a potent anticonvulsant, effective in the
treatment of status epilepticus. It does not possess neuroprotective
activity.
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RESPIRATORY SYSTEM
Depresses the ventilation, mostly pronounced effect seen in COPD
patients. Produces transient apnoea after rapid administration of large
doses. It also depresses the swallowing reflex and upper airway activity.
CARDIOVASCULAR SYSTEM
Decreases blood pressure as like other induction agents, more
pronounced in hypovolemia patients.
CLINICAL USES
PREOPERATIVE MEDICATION
Most commonly used oral preoperative drug for children. It is
effective for producing sedation and anxiolysis.
Dose: 0.25mg/kg
INTRAVENOUS SEDATION
Dose : 1-2.5mg i.v
Onset : 30-60sec
Time to peak effect :  3-5min
Duration of sedation :  15-80min
Exaggerated response on ventilation in the presence of opioids and
other CNS depressant drugs. Increasing age greatly increases the
pharmacodynamic sensitivity to the hypnotic effects.
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INDUCTION OF ANAESTHESIA
Dose: 0.1-0.2 mg/kg IV over 30-60sec. Onset of unconsciousness
is facilitated by the preceding injection of small dose of opioid.
Exaggerated cardiovascular responses seen in the presence of other CNS
depressant drugs like propofol and thiopentone.
MAINTENANCE OF ANAESTHESIA
Supplemental effect with opioids and propofol. Produces Dose-
dependent decrease in the requirement of volatile anaesthetics. .
POSTOPERATIVE SEDATION
Loading dose             : 0.5 - 4mg IV
Maintanence dose      : 1-7mg/hr IV
Emergence time is increased in elderly, obese and severe liver
disease patients.
SIDE EFFECTS
Physical and psycological dependence with withdrawal symptoms.
Oversedation and seizure like activity (paediatrics), Euphoria, Reduced
alertness, confusion, hallucinations, dizziness, ataxia and anterograde
amnesia, Skin rash, pruritus and Anaphylaxis.
Fatal complications include
Respiratory depression and respiratory arrest, Hypotension.
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PRECAUTIONS
Dose should be reduced in elderly and debilitated patients.
OVERDOSAGE
Sedation, confusion, impaired coordination, muscle relaxation.
Areflexia, hypotension, cardio-respiratory depression, apnoea and coma.
Treatment is supportive and symptomatic. In severe intoxication
benzodiazepine antagonist Flumazenil is indicated.
36
PHARMACOLOGY OF LIGNOCAINE24
Lignocaine is local anaesthetic, which belongs to the amide group
of anaesthetic agents. It is used in wide range of anaesthetic applications.
It is also useful in other systemic diseases such as cardiac arrhythmias
associated with myocardial infarction and in status epilepticus. Adult
patients with normal cardiac output, hepatic function, and hepatic blood
flow, an initial bolus dose  of lidocaine 1.5- 2 mg/kg, followed by a
infusion dose of 1 to 4 mg/min should provide therapeutic plasma
lidocaine concentrations of 1 to 5 µg/ml.
CH3
CH3
NH    CO    CH2   N CH2CH3
CH2CH3
HCl,H2O
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Physical properties
TABLE.IV
Relative potency 1
Pka 7.9
Plasma protein binding 70%
Structure Amide
Stability +++
Molecular weight 234
Adrenaline compatibility +++
Maximum dosage 3mg/kg, (with adrenaline 7 mg/kg)
Lipid solubility 2.9
Elimination half time 96 min
Clearance 0.95 l/min
Toxic plasma concentration More then5µg/ml
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Pharmacokinetics
Lignocaine is readily absorbed from the mucous membranes and
damaged skin and also from the injection sites (muscle).
After an intravenous dose, lignocaine is fastly distributed into
highly perfused and vascular tissues followed by redistribution into the
skeletal muscle and adipose tissues.  About 60-80% of the lignocaine is
bound to alpha-1 acid glycoprotein and it depends on the concentration of
the drug used.
The plasma concentrations of the lignocaine fastly decrease after
an intravenous dose with a t1/2 of less than 30 minutes. When infusions
are given for a longer time, the elimination half-time may be prolonged
for longer than 24 hours.
Lidocaine is highly metabolized in the liver and alterations in the
hepatic blood flow can affect the pharmacokinetics of the drug. Reduced
clearance of this agent is found in patients with congested liver and in
alcoholic liver disease.
The active metabolite is mono-ethylglycine xylidide, which may
also accumulate in patients with reduced cardiac output.
Metabolism of lignocaine is not affected by renal impairment but
the accumulation of its active metabolite can lead to toxicity. The
progressive increase in the concentration of AAG (alpha-1 acid
glycoprotein) as seen after lignocaine during its infusion in these patients.
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Surface application of lignocaine gives rise to slow rise in serum
concentrations. Acceptable plasma lignocaine concentrations have been
produced by local application jelly in certain procedures such as
bronchoscopy.
Uses of lignocaine
TABLE.V
Clinical use
Concentration
(%)
onset
Duration
(min)
Recommended
maximum single
dose(mg)
Topical 4 % fast 30 – 60 300
Infiltration 0.5 – 1 % fast 60 – 240 500 with
epinephrine
IVRA 0.25 – 0.5 % fast 30 – 60 300
Peripheral
nerve block
1 – 1.5 % fast 60 – 180 500 with
epinephrine
Epidural 1.5 – 2 % fast 60 – 120 500 with
epinephrine
Spinal 1.5 – 5 % fast 30 – 60 100
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Lignocaine is a local anaesthetic widely used by injection and for
local application to mucous membranes. The speed of onset and
absorption into the circulation depend upon the addition of
vasoconstrictors during application.
The dosage required in peripheral nerve blocks depends upon the
route of administration and the site of administration. It is used along
with adrenaline to increase its efficacy and the time of action. As a 1%
solution, it is used for sympathetic nerve block in doses of 5 ml for
cervical and in 10 ml doses in lumbar block.
In epidural anesthesia, 2 to 3 ml solution is needed for each
dermatome, but the total doses recommended are not to exceed 30 ml and
a maximum of 2% concentration.
For continuous epidural anesthesia, the maximum doses should not
be repeated more than once in 90 minutes. A hyperbaric solution of 1.5%
lignocaine in 7.5% glucose has been   used for spinal anaesthesia. Doses
up to 1 ml of solution have been used for obstetric surgeries.
For intravenous regional anesthesia, a 0.5% solution has been used
in up to 50 ml.
Its use as an anti-arrhythmic agent has been proved for many
decades. Its specific use is in the treatment of ventricular
tachyarrhythmias. It is also the drug of choice for ventricular arrhythmias
associated with acute myocardial infarction and is used in
cardiopulmonary resuscitation and ventricular fibrillation, when there is
no response to cardioversion. In cardiopulmonary resuscitation, it is given
41
as a single dose of 100 mg. In other conditions, it is given as a bolus dose
followed by an infusion of 1 to 1.5 mg/kg body weight as a direct
intravenous injection at the rate of 25 mg/min. If no effect is seen in 5
minutes, the loading dose may be repeated to a maximum dose to a
maximum dose of 2000 to 3000 mg in 1 hour. It is rarely necessary to
continue the infusion for longer than 24 hours.
Epilepsy is another indication in situations such as status
epilepticus when diazepam and phenytoin are ineffective. In adults, 100
mg may be given by slow intravenous injection followed by an infusion
at the rate or 1 to 2 mg per minute. Occasionally, recurrence of seizures
may be seen on withdrawal of prolonged lignocaine therapy.
Lignocaine has been used to attenuate the pressor response induced
by intubation.
In certain pain syndromes such as diabetic neuropathy and in other
chronic painful disorders, lignocaine has proved to be useful. Other
painful conditions such as perineal trauma as in episiotomy benefit with
local spray of 5% lignocaine. Spinal anesthesia and epidural anaesthesia
are the main and important uses of lignocaine.
ADVERSE EFFECTS
Central Nervous System
Reports of suspected psychotic reactions associated with lignocaine
have been published in 6 patients given lignocaine for cardiac
arrhythmias.
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Cardio Vascular System
Lidocaine  is  essentially  devoid  of  effects  on  the  ECG  or
cardiovascular system when the plasma concentration remains <5 µg/ml
cardiovascular side effects at therapeutic cocentrations are rare, except in
patients with pre-existing compromised ventricular function. Conduction
disturbances are rare. High plasma lidocaine concentrations may lead to
arrhythmias, hypotension, heart block, and cardiac- respiratory arrest.
Allergic Reaction
Allergic reaction following lignocaine includes itching, skin rash,
swelling of skin, Difficulty in breathing.
Clinical effects of overdose
TABLE.VI
Plasma lidocaine
concentration (µg/ml) Effect
1 – 5 Analgesia
5 – 10 Circumoral numbness,Tinnitus,
Skeletalmuscle twitching,
Systemic hypotension,
myocardial depression
10 – 15 Seizures
Unconciousness
15 – 25 Apnea
Coma
More than 25 Cardiovascular depression
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TREATMENT FOR OVERDOSE
Severe reactions
Immediately stop the drug administration; monitor the vitals.
Airway maintenance with 100% administration of oxygen.
Circulatory depression: vasopressors and intravenous fluids.
Seizures: Diazepam in 2-5mg increments, or an ultra-short-acting
barbiturate (such as thiopental or thiamylal) in 50 to l00 mg increments,
is given.
Skin: Fixed drug eruptions have been described.
Precautions
An intradermal test dose is always safe before lignocaine is used
for any injectable anaesthesia. It should not be used in patients with
hypovolemia and heart block or by other conduction disturbances. In
patients with cerebrovascular disorders, lignocaine should be used with
caution, as it may reduce cerebral blood flow.
Its use with other drugs such as beta blocking agents is rather
unsafe, as the concentration of lignocaine in the plasma may be increased.
Its use with cimetidine has been extensively studied.This drug reduces the
lignocaine clearance from the plasma. Ranitidine has not been shown to
have any effect on lignocaine kinetics. Lignocaine should not be used to
treat arrhythmias induced by cocaine intoxication.
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Lignocaine is not safe in patients with porphyria, because in animal
studies it has been shown to be a porphyrinogenic substance. Smokers
have been shown to have a reduced systemic bioavailability of
lignocaine.
Antiarrhythmic
loading dose : 2% Lignocaine 1.5 mg/kg
(without perservative)
Infusion doae : 1 to 4 mg/min (20 to 50 µg/kg/min)
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REVIEW OF LITERATURE
Lewis  CB  et  al 15(1948) used thiopentone sodium for tracheal
intubation without using neuromuscular blocking agents. In 200 patients,
either a blind nasal or direct oral intubation was done after thiopental
500–750 mg intravenously. There were two failures in the blind nasal
group and six in the direct laryngoscopy group. Lewis encountered
problems like coughing, laryngospasm. He demonstrated that adequate
conditions for intubation could be achieved using thiopentone sodium
alone.
Himes et al8 (1977) studied the interactions between lidocaine and
the anesthetics N2O and halothane and confirmed that lidocaine reduced
the dose of N2O and Halothane for achieving the depth of anaesthesia in
intraoperative period.
Poulton  et  al 18 (1979) compared the effectiveness of intravenous
lidocaine and bronchodilator inhalation treatment in patients with chronic
obstructive pulmonary disease (COPD) for rapid suppression of cough.
Both lidocaine and bronchodilator inhalation treatments were equally
effective for rapid cough suppression in patients with COPD.
Cormack RS, Lehane et al4 (1984) studied difficult tracheal
intubation in obstetric patients. They documented that the laryngeal view
during direct laryngoscopy showed a fair inter observer reliability and
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poor intra observer reliability, even when done by physicians well
familiar with this rating system under standardized conditions.
Yukiola  et  al32 (1985)   studied the cough suppressant effect of
various doses of intravenous lidocaine during tracheal intubation. He
found that significant suppression of cough was achieved when 2 mg/kg
of lidocaine was injected intravenously, between 1 and 5 min before
attempting intubation. Cough reflex was suppressed completely when
plasma concentrations of lidocaine exceeds 3 µg/ml.
Keaveny et al13 (1988)  showed the results of  using two different
doses of propofol 2.5 and 3 mg/kg, lignocaine 1.5 mg/kg, fentanyl 2µg
/kg for assessing the intubating conditions. Clinically acceptable
intubating conditions were obtained in 96.7% of patients in group
receiving 2.5 mg/kg propofol compared to 100% in group  receiving 3
mg/kg  propofol without significant hemodynamic changes and 100%
success can be obtained with 3 mg kg of propofol .
Ben Shlom et al1 (1990) studied and found that   Midazolam acts in
synergism with fentanyl for inducing anaesthesia. 25% of the ED50 of
fentanyl was required in combination with 23% of the ED50 for
midazolam to achieve the ED50 of  the  combination.   Midazolam  was
found to act in synergism with fentanyl for induction of anaesthesia. This
synergistic action is due to mutual potentiation between opioids and
benzodiazepines receptors.
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Saarnivaara et al26 (1991) studied the intubating conditions and
cardiovascular changes following administration of propofol alone or in
combination with alfentanil. He reported that only 5 out of 13 patients
(38%) had proper intubating conditions. He found good to moderate
intubating conditions in 79% of patients receiving a combination of
propofol 2.5 mg/kg with alfentanil 30 µg/kg.
Short  et  al27 (1991) studied the synergistic interactions between
propofol and midazolam for induction of anaesthesia. The exact
mechanism for this action is not known, but hypothesised to be an
interaction at CNS GABA -A receptors. Propofol dose requirement was
reduced to 52% in the presence of midazolam.
Mulholland et al17 (1991) studied intubation with propofol
augmented with intravenous lidocaine. He found that propofol 2.5 mg/kg
suppressed the laryngeal reflexes which was augmented by the cough
suppressive effects of lignocaine1.5 mg/kg.
Hookah et al9 (1991)  showed  the  induction  of  anesthesia  with
protocol in combination with lignocaine 1.5 mg/kg. This study compared
the ease of performing laryngoscopy and endotracheal intubation without
using muscle relaxants after the induction of anaesthesia with either
propofol or thiopentone in 106 patients posted for elective surgery.
Thiopentone sodium (5 mg/kg) or propofol (2.5 mg/kg), augumented with
lidocaine (1.5 mg/kg) and alfentanil (30 µg/kg), were used. Jaw
relaxation, visualisation of the larynx, vocal cords position, ease of
48
intubation and the tracheal tube tolerance are assessed. Jaw relaxation and
open vocal cords were found in most patients in both groups.
Visualisation of the larynx was good in 60 patients (46%) and intubation
was easy in 48 (22%) of the patients given thiopentone and propofol,
respectively.
Barker et al2 (1992) studied the difference in laryngeal reflexes on
intubation with propofol and thiopentone sodium. It showed suppression
of laryngeal reflexes by propofol and this may account for the lower
incidence of laryngospasm after induction of anaesthesia with propofol in
comparison with thiopentone.
Davidson et al5 (1993)   showed the effect of intravenous lidocaine
on the tracheal intubation after induction of anaesthesia with propofol and
alfentanil. He found intubating conditions were better and there was less
coughing when lignocaine was given before propofol and alfentanil
           Grange et al6 (1993) showed the effect of lignocaine or alfentanil
with propofol for tracheal intubation without the use of muscle relaxants.
Forty five patients posted for elective surgery were randomly allocated to
receive either 0.9% saline group (control), alfentanil 20µg/kg group, or
lignocaine 1.5 mg /kg group prior to induction with propofol 2.5 mg/ kg
and to assess the ease of intubation. Alfentanil group shows better
intubating conditions in 93% of patients compared to 60% in each of the
groups pre-treated with lignocaine. He showed pretreatment with
lignocaine was no better than saline.
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Hiller et al8 (1993) studied in children, the tracheal intubation after
induction of anaesthesia with propofol, three different doses of alfentanil
and lidocaine without using neuromuscular blockers. His studies showed
that the best intubating conditions in children were produced by propofol
3.5 mg/kg and alfentanil40 µg/kg.
Kazama et al14 (1997)  studied  the  reduction  of  the  CP50 values  of
propofol by using fentanyl and the hemodynamic responses to various
noxious stimuli. He concluded that combined usage of Propofol and
fentanyl suppressed motor and hemodynamic reactions to various noxious
stimuli.
Grant et al7 (1998) assessed intubating conditions in three groups
of  60  patients,  at  3  different  doses  of  remifentanil.  The  patients  were
premedicated with temazepam and anaesthesia was induced with propofol
2 mg/kg and remifentanil 0.5, 1.0, or 2 µg/kg. Overall intubating
conditions were regarded as acceptable in 20%, 50% and 80% of patients
respectively. Remifentanil 2 µg/kg and propofol 2 mg/kg produced the
best intubating conditions.
Stevens et al28 (1998) studied tracheal intubation by remifentanil
and propofol without muscle relaxants on ambulatory surgical cases.
Klemola et al15 (2000) studied the comparative intubating
conditions after remifentanil-propofol and alfentanil-propofol without
neuromuscular blocking agents. He concluded that the combination of
remifentanil 4 µg/ kg and propofol 2.5 mg/kg provided satisfactory
intubating conditions without eliciting any cardiovascular response.
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Jabbour-Khoury12 et al (2003) in their study found that alfentanil
produced better intubating conditions than fentanyl both of which were
used in combination with lidocaine and propofol in the absence of muscle
relaxants. He concluded that Propofol-Fentanyl combination could be
used as an alternative technique for tracheal intubation in patients
contraindicated to neuromuscular blocking agents.
Trabold et al29 (2004) studied a combination of Sevoflurane, N2O
and remifentanil and concluded that this combination provided acceptable
conditions for tracheal intubation in children and could be used as an
acceptable alternative to intravenous induction and neuromuscular
blockers.
Woods et al31 (2005), studied the tracheal intubation with propofol
and fentanyl, remifentanil, alfentanil without the usage of any
neuromuscular blocking agents.
Prakash et al20 (2006) showed that in the absence of neuromuscular
blocking agents, better intubation results were produced by the
combination of fentanyl-midazolam-propofol, when compared to
fentanyl-lidocaine-propofol.
Mohammadreza safavi, Azim honarmand et al18 (2008) conducted
a randomized study of tracheal intubation by remifentanil or alfentanil in
combination with thiopentone sodium in absence of muscle relaxants.
The study showed remifentanil 4µg/kg or alfentanil 40µg/kg with
thiopentone sodium 5mg/kg provided good to excellent intubating
conditions without using neuromuscular blocking agents.
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AIM
To compare the intubating conditions and cardiovascular changes
(post induction) between fentanyl, midazolam, propofol and fentanyl,
lignocaine, propofol groups without using neuromuscular blocking
agents.
52
MATERIALS AND METHODS
It is a prospective double blind randomized controlled study. The
study was approved by the ethical Committee.
Hundred patients undergoing elective general surgical procedure
under general anaesthesia with endotracheal intubation were included in
this study and randomly divided into two groups.
The Surgeons were duly informed about the study. The study was
during the period of April 2011 to April 2012 in the Department of
Anaesthesiology, Chengalpattu MedicalCollege, and Chengalpattu.
Group (M)
Fifty patients received propofol 2.5mg/kg, fentanyl 2µg/kg,
midazolam 0.03mg/kg.
Group (L)
Fifty patients received propofol 2.5mg/kg, fentanyl 2µg/kg,
lidocaine 1.5mg/kg.
Inclusion Criteria
ASA I&II
Age 20-50yrs
All cases requiring GA
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Exclusion Criteria
Not meeting inclusion criteria
Known and difficult airways
Patients with full stomach
Patients posted for emergency surgery
Hypertension,
Diabetes,
Ischemic heart disease
Reactive Airway Disease
Allergy to drugs
Randomization was done by draw of lots. The follow up of the
Patient  and  analysis  of  data  were  done  by  personnel  blinded  to  which
group belonged to. Drawing of lots for Randomization and preparation of
study was prepared by a consultant who took no further part in the study,
the anaesthetist performing and scoring the laryngoscopy grading and
tracheal intubation was blinded to the randomization group and the rest of
the study was conducted by investigator who was blinded to the drug
injected.
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MATERIALS
1. Inj.Profopol 1% - 10 ml vial
2. Inj.Fentanyl  Citrate – 2ml ampoule
3. Inj.Glycopyrrolate – 1ml ampoule
4. Inj.Midazolam – 5ml vial
5. Inj.Lignocaine Hydrocholoride (xylocard) - 50 ml vail
6. Disposable 5ml syringes
7. McIntosh Laryngoscope with 3 and 4 size blades
8. Endotracheal tubes of varying sizes
9. Emergency drugs
10. Difficult Intubation Strategies
PRE OPREATIVE PREPARATION
All the Patients were admitted and they underwent relevant
investigations. Preoperatively informed, written consent was obtained
from the Patients.
Complete Hemogram,
Bleeding time,
Clotting time
Blood -     urea, sugar
Serum         - creatinine
Serum - Electrolytes
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X ray Chest
Electrocardiogram
Other relevant investigations were obtained on the basis of the
conditions of the Patient
ANAESTHESIA PROTOCOL
Pre operative visit was done to allay anxiety and good rapport was
established with the patient.
All the patients were given pre operative night sedation with tablet
diazepam 10mg and tablet ranitidine 150mg orally.
PREMEDICATION
All the patients were premedicated with Inj.Glycopyrrolate 4µg/kg
body weight intramuscularly45 mins before surgery. Basal pulse rate and
Blood Pressure were recorded.
MONITORING
Non Invasive Automated BP
Electrocardiogram
Pulseoximetry
ETCO2
Neuromascular Monitoring
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Patients shifted to operating table after 45 minutes. In the operating
room patients were connected to baseline monitors, then intravenous
access established with 18 gauges cannula and intravenous fluids started.
Pulse rate, Blood pressure, ECG and SpO2 were recorded.
PRE-OXYGENATION
Pre-oxygenation was done with 100% oxygen for 5 minutes.
ADMINISRATION OF STUDY DRUG
Patients In M Group received propofol 2.5mg/kg, fentanyl 2 µg/kg,
midazolam 0.03 mg/kg, and; L group received propofol 2.5mg/kg,
fentanyl 2 µg/kg, lignocaine 1.5 mg/kg. Fentanyl and midazolam were
administered 5 min and lignocaine 20 s before induction of anaesthesia
with propofol.
After loss of response to command the patient’s lungs were
ventilated via a anatomical facemask. Laryngoscopy was done 40 s after
propofol administration. The patient’s trachea was intubated with an
appropriate size cuffed tracheal tube and the cuff was inflated.
Anaesthesia was maintained with 66% nitrous oxide in oxygen and 0.6%
isoflurane using a carbondioxide absorption circuit. After intubation the
haemodynamic measurements were obtained up to 5mins of post
intubation period.
The whole intra operative and post operative period were
uneventful.
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Summarized protocol
TABLE.VII
Time M Group L Group
-5 min Fentanyl + Midazolam Fentanyl + lignocaine 20
sec before induction
0 Propofol Propofol
+ 40 s Laryngoscopy and
tracheal intubation
Laryngoscopy and tracheal
intubation
ASSESSMENT OF INTUBATION CONDITIONS
Assessment of intubating conditions include: ease of laryngoscopy,
the vocal cord position, the cough, and limb movement. Laryngoscopy
was graded as easy (jaw relaxation), fair (jaw not fully relaxed), and
difficult (poor jaw relaxation). Intubating conditions were regarded as
excellent (all qualities were excellent), good (all qualities were either
excellent or good), and poor (the presence of a single quality listed under
poor). Excellent and good intubating conditions are comes under
clinically acceptable; poor intubating conditions were regarded as
clinically not acceptable
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TABLE.VIII
Variable
Intubation conditions
Clinically acceptable Not acceptable
Excellent Good Poor
Laryngoscopy Easy Fair Difficult
Vocal cords
position
Abducted Intermediate Closed
Coughing None Diaphragm Sustained (> 10 s)
Movement of
the limbs
None Slight Vigorous
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STATISTICAL   ANALYSIS
Heartrate, mean arterial pressure, intubating conditions score
include laryngoscopy, limb movement, vocal cord position, coughing are
compared. All recorded data were entered SPSS 16.0V Software for
determining the statistical significance. Mean and standard deviation for
continuous variable and Percentages are given for categorical variables.
Student’s  t  test  was  used  to  compare  the  two groups  on  mean  values  of
various parameters. Chisq test was used to compare the two groups for
categorical variables. P value taken for significance is <0.05.
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LIST OF SURGICAL PROCEDURES
TABLE.IX
S.No Surgery M Group L Group
1 Herniorraphy 15 15
2 Fibroadenomaexicision 12 10
3 Appendicectomy 4 8
4 Gynaecomastia
Exicision
3 2
5 Hydrocele eversion 6 5
6 Cholecystectomy 2 2
7 Epigastric hernia 4 4
8 Incisional hernia 4 4
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OBSERVATION AND RESULTS
Hundred patients under this study were categorized into two
groups. They comprised of both sexes with age ranging from 20-50 years
The  age  and  sex  were  equal  in  all  two  groups.  P  value  was  not
significant in the study done (P value is more than 0.05).
DEMOGRAPHIC PROFILE
AGE
The range of age in both group M and group L was 20 – 50 years.
The average age in both groups was similar. The table describes the
distribution of age.
TABLE - X
GROUP
20-30 31-40 41-50 TOTAL
N (%) N    (%) N    (%) N   (%)
M Group 30 (60%) 13 (26%) 7 (14%) 50 (100%)
L Group 20 (40%) 18 (36%) 12 (24%) 50 (100%)
TOTAL 50 31 19 100
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MEAN AGE OF PATIENTS BY GROUPS
The mean age group for M was 31.44±8.68 and L group
34.52±8.82 there is no statistically significant difference between M and
L age group, with the P value 0.08.
SEX
This table shows the sex distribution of M and L groups. There is
no significant difference between M and L group, p value - 0.52.
TABLE - XI
Group
Male
N (%)
Female
N (%)
Total P value
M 32 18 50
0.52
L 35 15 50
TOTAL 67 33 100
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WEIGHT
This  table  shows  the  mean  weight  of  the  patients  in  these  two
groups. Mean value of M group is 49.82±6.157, Mean value of L group is
52.15±6.63. The P value is 0.08
TABLE - XII
Group N Mean + SD
Minimum
weight
(kgs)
Maximum
weight
(kgs)
P
value
M 50 49.82 +
6.157
32 64 0.08
L 50 52.15 + 6.63 36 62
HEIGHT
This table shows the mean height of the patients in these two
groups. The height  for M group 144cms to 170cms. The mean height for
M group is 159.32±6.912.The height for L group 148cms to 168cms. The
mean height for L group is 160.68±6.31.There is no significant difference
between M and L group for height with t value of 1.028 and also P value
of 0.31.
64
TABLE – XIII
Group  N Mean ± Std.Deviation
Minimum
Height
(cms)
Maximum
Height
(cms)
P value
M 50 159.32±6.912 144 170 0.31
L 50 160.68±6.31 148 168
Mallampatti Grading (MPC I/II)
Airway was assessed by using the Mallampatti grading. Airways of
both group were compared and  In M group 44 (88%) patients, In L group
45(90%) patients comes under MPC grade –I, In M group 6 (12%)
patients, In L group 5(10%) patients comes under MPC grade –II. chisq
value for this grading 0.012, P value  is 0.75.There is no statistical
significance between  these two groups.
TABLE - XIV
Group Grade Frequency(N)
Percentage
(%)
Total P  value
M
I 44 88 50
0.75II 6 12 100
L
I 45 90 50
II 5 10 100
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Cormack and Lehane Laryngoscopic view (CLG I/II):
This classification describes the best view during laryngoscopy,
Laryngoscopy view of both groups were compared and  In M group 45
(90%) patients, In L group 47(94%) patients comes under CLG grade–I,
In M group 5 (10%) patients, In L group 3(6%) patients comes under
MPC grade–II. Chisq value for this grading 0.54, P value is 0.4. There is
no statistical difference between two groups.
TABLE - XV
Group Grade
Frequency
(N)
Percentage
(%) Total P value
M
I 45 90 50
0.4II 5 10 100
L
I 47 94 50
II 3 6 100
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Duration Laryngoscopy (S)
Duration of the laryngoscopy is defined as the time from start of
laryngoscopy until tracheal intubation and removal of laryngoscope blade
from the mouth. Laryngoscopy was performed 40 sec after propofol
administration, maximum laryngoscopy duration in M group 17sec, L
group is 19sec, minimum duration of both groups are respectively 11secs
(M), 12 secs (L). Mean laryngoscopy duration of both groups are
respectively 13.62secs (M), 15.4secs (L). Duration of laryngoscopy was
statistically significant between these two groups.
TABLE – XVI
Group  N
Mean±Std.
Deviation
(S)
Minimum
Duration
(S)
Maximum
Duration
(S)
P value
M 50 13.62±1.652 11 17
0.00
L 50 15.4±2.1 12 19
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LARYNGOSCOPY
Laryngoscopy is graded as easy, fair and difficult. Easy, fair comes
under clinically acceptable intubating conditions. Difficult laryngoscopy
comes under clinically unacceptable intubating condition. In M group
laryngoscopy was easy 50 (100%) in all patients whereas in L group
32(64%) had easy laryngoscopy, 18(36%) had difficult laryngoscopy. P
value is 0.00(less than 0.05). M group had better laryngoscopy than L
group.
TABLE - XVII
Group Grade Frequency(N)
Percentage
(%) P value
M Easy 50 100
0.00
L
Easy 32 64
Difficult 18 36
0
5
10
15
20
25
30
35
40
45
50
L Grp M Grp
EASY
difficult
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Vocal Cord
During laryngoscopy vocal cord position is classified as abducted,
intermediate (clinically acceptable intubating condition), closed(clinically
unacceptable intubating condition).Vocal cord position is abducted 50 out
of 50 patients in M group,43 out of 50 patients in L group .Seven patients
in the L group had closed vocal cords requiring administration of
rocuronium before successful intubation.
TABLE - XVIII
Group
Vocal
cord
position
Frequency
(N)
Percentage
(%)
Rocuronium
Requirement
P
Value
M Abduct 50 100 0 0.006
L Abduct 43 86 0
Closed 7 14 7
0
10
20
30
40
50
L Grp M Grp
43
50
7
Abduct Closed
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Cough
During laryngoscopy and intubation, coughing is graded as no
cough, diaphragmatic cough (clinically acceptable), sustained coughing
more than 10secs (clinically unacceptable). Twenty two patients (44%) in
the L group had sustained coughing (> 10 s) on intubation compared with
the M group 5(10%) although this is statistically significant. P value is
0.00
TABLE - XIX
Group Cough Frequency   (n) Percent (%) P value
M
Coughing 5 10
0.00
None 45 90
Total 50 50
L
Coughing 22 44
None 28 28
Total 50 50
0
5
10
15
20
25
30
35
40
45
L M
22
5
28
45
Cough
Coughing
NONE
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LIMB MOVEMENTS
Limb movement is graded as no movement, slight movement
(clinically acceptable), vigorous movement (clinically unacceptable). In
the L group 18 patients (36%) had vigorous limb movement compared
with no limb movement in the M group (P value is 0.00).
TABLE - XX
Group Limb movement Frequency(n)
Percentage
(%)
P value
M Limb movement
(none)
50 100
0.00
L
Limb movement
(none)
32 64
Vigorous 18 36
0
10
20
30
40
50
L Grp M Grp
32
50
18
Limb Movement
NONE
vigrous
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Overall intubating condition
This table shows the overall intubating condition of both groups. M
group shows better intubating conditions 40 out of 50 patients (80%),
compare to 28 out of 50 patients (56%) in L Group. Clinically UN
acceptable intubating conditions in both groups respectively 10(20%) in
M (g), 22(44%) in L (g). There is no rocuronium requirement in M group.
In L group seven are required rocuronium, over all intubating conditions
better in M group.
TABLE - XXI
Group
Intubating
conditions
Frequency
(n)
Percentage
(%)
Total
Rocuronium
Requirement
P
value
M
CA 40 80 50
0 0.01C-UA 10 20 100
L
CA 28 56 50
7C-UA 22 44 100
CA – Clinically acceptable C-UA – Clinically unacceptable
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HEART RATE (BEAT / MINUTE)
The maximum rise in heart rate was observed during intubation
and at one minute following intubation. The rise was modest of about 2-3
beats per minute. It started declining to baseline values at fourth minute.
There was a further decline in heart rate from the baseline values at sixth
and seventh minute. No rhythm disturbances were observed. There is no
significant difference in heart rate of both groups. P value is not clinically
significant.
90.72
88.58
94.34
93.74
91.7
90
88.12
89.18
87.88
93.88
92.06
90.64
90.1
88.04
84
86
88
90
92
94
96
PRE_HR POSTHR PI1HR PI2HR PI3HR PI4HR PI5HR
L GRP M GRP
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TABLE – XXII
DISTRIBUTION OF MEAN ± STANDARD DEVIATION OF
HEART RATE BY GROUPS
Events M Group
(n = 50)
L Group
(n = 50)
P Value
Pre-induction 89.18 ± 3.56 90.72 ± 5.59 0.10
Post-
induction 87.88 ± 3.9 88.58 ± 4.03
0.38
POST – INTUBATION
1 min 93.88 ± 6.48 94.34 ± 4.44 0.68
2 min 92.06 ± 6.27 93.74 ± 4.36 0.12
3 min 90.64 ± 6.56 91.7 ± 4.23 0.34
4 min 90.1 ± 6.49 90 ± 4.31 0.93
5 min 89.26 ± 6.24 88.12 ± 4.36 0.94
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MEAN ARTERIAL PRESSURE (mm/Hg)
Statistical significance is not observed between the two groups up
to induction. (P value more than 0.05).  After induction there is
significant difference on mean arterial pressure between these two groups
till  the  end  of  the  study.  (P  value  less  than  0.00).  Between  these  two
groups better hemodynamic stability was observed in M group.
96.06
94.12
115.52
111.42
108.22
103.86
100.64
96.32
92.82
110.32
106.34
102.82
98.98
96.44
80
90
100
110
120
PREMAP POSTMAP PI1MAP PI2MAP PI3MAP PI4MAP PI5MAP
L GRP M GRP
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TABLE -XXIII
DISTRIBUTION OF MEAN ± STANDARD DEVIATION OF
MEAN ARTERIAL PRESSURE BY GROUPS
Events
M Group
(n = 50)
L Group
(n = 50)
P Value
Pre –Induction 96.32 ± 4.98 96.06± 4.86 0.79
Post –Induction 91.7 ± 5.43 94.12 ±491 0.02
POST  INTUBATION
1 min 110.32 ± 3.9 115.52 ±4.47 0.00
2 min 106.34 ± 4.52 111.42 ± 4.53 0.00
3 min 102.82 ± 4.05 108.22  ±4.59 0.00
4 min 98.98 ± 4.09 103.86±  4.61 0.00
5 min 96.44 ± 3.53 100.64  ±3.93 0.00
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RESULTS
There is no statistical significance in patient characteristics
between these two groups (Table X to XIII). The Mallampatti grading,
Cormack and lehane laryngoscopy grading, and the laryngoscopic
duration was compared in both groups. There is no statistical significance
in mallampatti and Cormack – lehane grading between these two groups,
the statistical significance was observed in laryngoscopy duration (P
value is 0.00).
Mask ventilation was easy in all patients. Intubation attempt was
successful in all (100%) patients in the M group and in the L group 43 out
of 50 patients (86%) had successful intubation. There is no rocuronium
requirement in the M group and in the L group seven patients required
rocuronium (P value 0.01). Patients who are all received rocuronium were
intubated successfully.
          Overall clinically acceptable intubating conditions was 40 out of 50
patients (80%) in the compared to 28 out of 40 patients (56%) in L group.
This difference was statistically significant (P value 0.01) (Table 11).
Laryngoscopy was easy in all patients in the M group. Laryngoscopy was
difficult in 18 (36%) out of 50 patients in the L group (P value 0.00).
seven patients in the L group had closed vocal cords requiring
administration of rocuronium before intubation (P value 0.01).
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Twenty two patients (44%) in the L group had sustained coughing
(> 10 s) on intubation compared with the M group 5(10%) although this
is statistically significant. P value is 0.00
In the L group 18 patients (36%) had vigorous limb movement
compared with no limb movement in the M group (P value is 0.00).
Cardiovascular responses to induction and intubation are compared
in both groups. There is no significant difference in heart rate of both
groups. Statistical significance is not observed between the two groups up
to induction (P value more than 0.05).  After induction there is significant
difference on mean arterial pressure between these two groups till the end
of the study (P value less than 0.00). Between these two groups better
hemodynamic stability was observed in M group.
Oxygen saturation was maintained between 96% - 100% before as
well as after induction of anaesthesia and tracheal intubation. There were
no episodes of laryngospasm, bronchospasm, masseter spasm, or
generalized rigidity were observed.
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DISCUSSION
Endotracheal intubation without usage of neuromuscular blocking
agents is successfully described in this study. This technique enables us to
assess the airway by laryngoscopy to ascertain if oxygenation is possible.
This technique is useful in both expected and unanticipated difficult
intubation, in cases where muscle relaxants are either contraindicated
(e.g. myopathies) or not required to facilitate surgical access.
Demographic profile
The two groups were comparable with respect to age, sex, height
and weight (Table X to XIII) in our study and are correlating with study
done by prakash et al20 whose study also shows no statistical difference in
patient characters.
Mallampatti grading
Airways of both group were compared and  44 patients (88%) in
the M group, 45 patients (90%) in the L group comes under MPC grade –
I, 6 patients (12%) in the M group , 5 patients(10%) in the L group comes
under MPC grade –II. There is no statistical significance between these
two groups. Prakash et al20 his study also showed no statistical difference
between two groups in Mallampatti grading.
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Cormack and lehane laryngoscopy grading
Laryngoscopy view of both groups were compared and  45 patients
(90%) in the M group, 47 patients (94%) in the L group comes under
CLG grade–I, 5 patients (10%) in the M group, 3 patients (6%) in the L
group comes under MPC grade–II. Thus the two groups did not differ
statistically with respect to laryngoscopic view.
Prakash et al20 study which also no statistical difference between
two groups in mallampatti grading.
Laryngoscopic duration
Duration of the laryngoscopy is defined as the time from start of
laryngoscopy until tracheal intubation and removal of laryngoscope blade
from the mouth. Laryngoscopy was performed 40 sec after propofol
administration, maximum laryngoscopy duration in M group duration
was 17sec, and L group it is 19 sec, minimum laryngoscopy duration of
both groups are respectively 11secs(M),12secs(L). Mean laryngoscopy
duration of both groups are respectively 13.62secs (M), 15.4secs (L).
Laryngoscopy duration was statistically significant between these two
groups.
Prakash et al20 showed no statistical difference between two groups
in laryngoscopy duration.
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Laryngoscopy
In M group laryngoscopy was easy  in all patients (100%) whereas
in L group 32(64%) had easy laryngoscopy, 18(36%) had difficult
laryngoscopy. It is statistically significant. In M group laryngoscopy was
better than L group.
Prakash et al20 study showed Laryngoscopy was easy in all patients
in the M group but difficult in two out of 40 patients in the L group
Lewis  et  al16 (1948) also showed in his study that there was
difficulty in performing laryngoscopy in six patients. He used thiopental
sodium as the sole agent to facilitate tracheal intubation without using
neuromuscular blocking agents
Vocal cord position
It is abducted in 50 out of 50 patients in M group, 43 out of 50
patients in L group. In the L (lidocaine) group seven patients had closed
vocal cords requiring rocuronium for intubation. It is statistically
significant (P value 0.01). This is in concurrence with prakash et al20
study which showed five patients in the L (lidocaine) group had closed
vocal cords and so these patients required rocuronium for intubation.
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Coughing
In our study twenty two patients (44%) in the L (lidocaine1.5
mg/kg) group had sustained coughing (> 10 s) on intubation compared
with five patients (10%) in the M (midazolam) group. This is statistically
significant. P value is 0.00.
Prakash et al20 study showed sustained coughing (> 10 s) in the L
group (17 patients) during intubation compared with the M group (10
patients).
Davidson et al5 (1993) studied tracheal intubation with propofol,
alfentanil and with or without intravenous lignocaine. His study showed
better cough suppressant effect in lignocaine.
Houlton et al19 (1979) study showed equal cough suppressant effect
in lidocaine compared to bronchodilators.
Yukiola et al32 (1985) study showed decreased incidence of cough
when 2 mg/kg of intravenous lidocaine was given one to five minutes
before intubation.
Hiller et al10 (1993) study showed lignocaine 1 mg/kg not enough
to suppress the cough. He concluded that higher dose of lignocaine was
required to suppress the cough reflex with propofol induction.
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Limb movement
In the L group 18 patients (36%) had vigorous limb movement
compared with no limb movement in the M group (P value is 0.00).  This
is in concurrence with Prakash et al20 study which showed that six
patients in the L (lidocaine) group had slight limb movement compared
with no limb movement observed in the M group.
Intubating conditions
In our study M group shows better intubating conditions in 40 out
of 50 patients (80%), compared to 28 out of 50 patients (56%) in L
Group. Clinically unacceptable intubating conditions in both groups was
respectively 10(20%) in M (g), 22(44%) in L (g). This difference was
statistically significant (P value 0.01) (Table XXI). There is no
rocuronium requirement in M group. In L group seven patients required
rocuronium, and over all intubating conditions were better in M group.
Prakash et al20 study showed better intubating conditions in
midazolam group compared to lignocaine group.
Lewis  et  al16 (1948) studied after administration of thiopentone
sodium 500-750 mg in 200 patients for oral intubation or blind nasal
intubation without muscle relaxants. There were two failures in the blind
nasal group.
Keaveny et al13 (1988) in his study used   propofol 3 mg/kg and
showed better intubating conditions.
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Barker et al2 (1992) study showed lower incidence of
laryngospasm and vocal cord movements following propofol induction
compared to thiopentone induction, and is due to greater depression of
laryngeal reflexes by propofol.
Grant et al7 (1998) study showed better intubating conditions with
propofol 2 mg/kg and pre treatment with remifentanil 2 µg/kg. This dose
was equal to 4 µg/kg of fentanyl.
Mulholland et al 17 (1991) study showed no significant difference
was found in the intubating conditions with intravenous pre-treatment
with lignocaine 1.5 mg/kg.
Grange et al6 (1993) observed no significant difference in the
quality of intubating conditions with intravenous pre-treatment with
lignocaine or alfentanil.
Klemola et al15 (2000) study showed better intubating conditions
was observed in remifentanil 4µg/kg –propofol 2.5 mg/kg comination.
Trabold  et  al29 (2004) study showed better intubating conditions
was observed when remifentanil 1µg/kg was given after propofol 2.5
mg/kg with midazolam 0.03 mg/kg.
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HEART RATE
In our study cardiovascular responses to induction and endo
tracheal intubation were compared with midazolam and lidocaine groups.
In both groups no difference in heart rate was found. (P value more than
0.05).This is in concurrence with prakash et al20 study that showed that
there is no statistical significance in heart rate between two groups.
Mulholland et al 17 (1991) study showed no difference in the heart
rate to intubation with propofol (2.5 mg/kg) induction with pre-treatment
with lignocaine 1.5 mg/kg.
Mean arterial pressure
In our study there was significant difference in mean arterial
pressure after induction between these two groups till the end of the
study. (P value less than 0.00). Between these two groups better
cardiovascular stability was observed in M group. This is in concurrence
with  Prakash  et  al20 study that showed that there was statistical
significance in mean arterial pressue between two groups. In his study
better cardiovascular stability was observed in M group compared to L
group.
Saarnivaara et al26 (1991) study showed better cardiovascular
stability in propofol 2.5 mg/kg with alfentanil 30 µg/kg pretreatment.
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Mulholland et al 17 (1991) study showed no difference in the mean
arterial pressure to intubation with propofol (2.5 mg/kg) induction with
pre-treatment with lignocaine 1.5 mg/kg.
Klemola et al15 (2000) study showed better cardiovascular stability
was observed in remifentanil 4µg/kg with propofol 2.5 mg/kg
combination.
 Trabold et al29 (2004) study showed better cardiovascular stability
was observed in remifentanil 1µg/kg was given after s 2.5 mg/kg with
midazolam 0.03 mg/kg.
SIDE EFFECTS
In our study there were no episodes of laryngospasm,
bronchospasm, masseter spasm, or generalized rigidity. This is in
concurrence with   Lewis et  al16 study which showed that problems like
coughing, laryngospasm occur during thiopentone induction alone
without using neuromuscular blocking agents.
The propofol (2.5 mg/kg) induction has greater depression of
laryngeal reflexes than an equipotent dose of thiopentone. The incidence
of laryngospasm was lower with propofol compared to thiopentone.13
The addition of fentanyl and midazolam potentiate the effects of
propofol and reduce the dose requirement of propofol. Both propofol and
midazolam has synergestic action due to interaction at GABA-A
receptors in the central nervous system. The propofol dose was reduced
by 52% in the presence of midazolam.27
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 Midazolam has synergistic action with fentanyl for induction of
anaesthesia. This synergistic effect is due to potentiation between opioids
and benzodiazepines.1
The cough suppressant effect of intravenous lignocaine is due to
brain stem depression.11 Lignocaine may act by anaesthetizing peripheral
cough receptors in the trachea and hypopharynx19 or by increasing the
depth of general anaesthesia8.
           Endotracheal intubation is a stronger stimulus than laryngoscopy.
Propofol with fentanyl combination was able to suppress motor and
hemodynamic reactions to various noxious stimuli. Laryngoscopy was
easier in most of the patients with either technique.14
The tracheal intubation without neuromuscular blocking agents are
not  advised   in  patients  with  a  full  stomach,  elderly  patients  and   those
with cardiovascular or cerebrovascular disease and in those patients
undergoing neurosurgery or ophthalmic procedures.
The potentially serious and undesirable side-effects of
succinylcholine are avoided and side effects such as anaphylaxis that can
occur with the use of non-depolarizing drugs are avoided. The short
acting opioids, such as remifentanil and alfentanil, when used in
combination with propofol for tracheal intubation are more advantageous
in the aspect of good depth of anaesthesia and also stable hemodynamic
profile .31 In our study we used fentanyl as a opioid in combination with
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midazolam, propofol and lidocaine. Midazolam has synergestic action
with fentanyl and propofol. So, the intubating condions and
cardiovascular responses were better in propofol, midazolam and fentanyl
group patients.
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CONCLUSION
I conclude that the propofol – fentanyl – midazolam combination is
better compared to propofol – fentanyl – lignocaine combination in
providing clinically acceptable conditions for intubation without
significant cardiovascular changes without the use of neuromuscular
blocking agents. Hence this combination can be a useful alternative
technique for tracheal intubation when neuromuscular blocking drugs are
contraindicated or need to be avoided.
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1. 39712 49 54 162 M I I 12 EASY ABDUCT NONE NONE CA No 91 99 88 96 99 113 97 108 95 105 95 100 94 98
2. 37756 40 55 151 F I I 12 EASY ABDUCT NONE NONE CA No 92 104 87 100 96 109 96 105 93 101 91 98 90 95
3. 39935 50 60 165 M I I 14 EASY ABDUCT NONE NONE CA No 89 102 86 99 97 114 95 110 94 106 93 104 92 101
4. 39585 40 55 163 M II I 15 EASY ABDUCT NONE NONE CA No 92 98 89 95 99 111 97 107 96 104 95 100 94 98
5. 39882 48 52 167 M I I 13 EASY ABDUCT Coughing NONE C-UA No 102 85 98 82 108 102 103 96 105 93 104 90 103 88
6. 39736 47 55 157 M I I 14 EASY ABDUCT NONE NONE CA No 88 94 84 90 94 112 92 108 91 104 90 101 88 98
7. 39788 27 38 160 M I II 14 EASY ABDUCT NONE NONE CA No 90 98 94 94 91 110 89 108 87 104 87 101 86 98
8. 36928 25 50 156 M I I 16 EASY ABDUCT NONE NONE CA No 91 101 90 96 90 108 88 106 86 103 85 99 85 96
9. 49420 26 50 149 F I I 17 EASY ABDUCT NONE NONE CA No 90 92 92 90 85 106 83 101 82 98 80 96 80 93
10. 48433 28 39 159 M I I 12 EASY ABDUCT NONE NONE CA No 86 93 93 90 87 111 85 106 84 102 84 98 84 95
11. 39933 25 50 164 M I I 11 EASY ABDUCT NONE NONE CA No 92 96 90 92 84 114 82 109 80 106 98 101 78 99
12. 40533 20 50 150 F I I 13 EASY ABDUCT NONE NONE CA No 88 92 86 92 95 109 95 105 92 103 91 98 90 95
13. 40439 20 48 152 F I I 14 EASY ABDUCT NONE NONE CA No 90 100 88 86 96 106 94 102 92 99 89 96 88 94
14. 40887 30 55 163 M I I 14 EASY ABDUCT Coughing NONE C-UA No 90 93 88 90 96 110 94 106 95 102 94 98 93 96
15. 41244 27 38 169 M I I 15 EASY ABDUCT Coughing NONE C-UA No 86 106 85 100 84 120 82 114 81 110 82 105 80 104
16. 41219 26 45 152 F I I 15 EASY ABDUCT NONE NONE CA No 89 101 92 97 90 115 88 116 87 106 86 103 85 100
17. 41728 27 36 154 F I I 16 EASY ABDUCT NONE NONE CA No 91 101 89 96 88 118 86 118 85 110 85 106 84 102
18. 41616 35 48 155 F I I 17 EASY ABDUCT NONE NONE CA No 88 102 87 96 96 112 94 108 93 104 92 100 90 96
19. 42298 29 50 165 M II II 12 EASY ABDUCT NONE NONE CA No 88 97 86 94 98 110 98 106 95 102 94 99 93 95
20. 41983 22 45 156 F I I 12 EASY ABDUCT NONE NONE CA No 87 102 81 100 83 118 81 113 80 109 78 105 98 101
21. 42558 20 45 144 F I I 13 EASY ABDUCT NONE NONE CA No 87 97 86 94 99 113 97 108 95 105 95 100 94 98
22. 42548 24 46 169 M I I 14 EASY ABDUCT NONE NONE CA No 88 96 88 94 96 109 94 105 93 101 91 98 90 95
23. 50313 33 55 165 M I I 15 EASY ABDUCT NONE NONE C-UA No 86 92 86 90 97 114 95 110 94 106 93 104 92 101
24. 42385 40 56 167 M I I 17 EASY ABDUCT NONE NONE CA No 90 85 86 80 99 111 99 107 96 104 95 100 94 98
25. 42552 48 53 163 M II II 14 EASY ABDUCT Coughing NONE C-UA No 91 98 90 92 108 102 105 96 105 93 104 90 103 88
26. 43033 25 49 152 F I I 13 EASY ABDUCT NONE NONE CA No 86 92 84 90 94 112 92 108 91 104 90 101 88 98
27. 47209 27 52 147 F I I 16 EASY ABDUCT NONE NONE CA No 88 93 86 82 91 110 90 108 87 104 87 101 86 98
28. 43222 31 56 164 M I I 12 EASY ABDUCT NONE NONE C-UA No 82 100 80 84 90 108 88 106 86 108 86 99 85 96
29. 44075 35 52 152 F I I 14 EASY ABDUCT NONE NONE CA No 86 98 86 94 85 106 83 101 82 98 80 96 80 93
30. 44082 22 47 156 F I I 15 EASY ABDUCT NONE NONE CA No 90 96 89 90 87 111 87 106 84 102 84 98 84 95
31. 32186 30 51 150 F I II 12 EASY ABDUCT Coughing NONE C-UA No 91 99 88 96 99 113 97 108 95 105 95 100 94 98
32. 32198 20 40 147 F I I 11 EASY ABDUCT NONE NONE CA No 92 104 90 100 96 109 94 105 93 101 91 98 90 95
33. 32199 30 46 160 M I I 15 EASY ABDUCT NONE NONE CA No 89 102 88 99 97 114 95 110 94 106 93 104 92 101
34. 32167 28 48 162 M II I 15 EASY ABDUCT NONE NONE CA No 92 98 90 90 99 111 99 107 96 104 95 100 94 98
35. 32039 23 52 165 M I I 14 EASY ABDUCT NONE NONE C-UA No 102 85 98 80 108 102 105 96 105 93 104 90 103 88
36. 30364 40 45 170 M I I 11 EASY ABDUCT NONE NONE CA No 88 94 86 90 94 112 92 108 91 104 90 101 88 98
37. 31262 27 49 149 F I I 13 EASY ABDUCT NONE NONE CA No 90 98 94 96 91 110 89 108 87 104 87 101 86 98
38. 30347 20 52 167 M II I 12 EASY ABDUCT NONE NONE C-UA No 91 101 90 96 90 108 88 106 86 103 83 99 85 96
39. 29121 37 43 155 F I I 14 EASY ABDUCT NONE NONE CA No 90 92 92 90 85 106 85 101 82 98 80 86 80 93
40. 30342 30 46 157 F I I 13 EASY ABDUCT NONE NONE CA No 86 93 93 95 87 111 85 106 84 102 84 98 84 95
41. 38360 30 50 160 M I I 12 EASY ABDUCT NONE NONE CA No 87 97 86 94 99 113 97 108 95 105 95 100 94 98
42. 38353 24 45 162 M II I 11 EASY ABDUCT NONE NONE CA No 88 96 84 95 96 109 94 105 93 101 91 98 90 95
43. 38129 40 40 165 M I I 15 EASY ABDUCT NONE NONE C-UA No 86 92 84 90 97 114 95 110 94 106 93 104 92 101
44. 30055 29 51 170 M I I 15 EASY ABDUCT NONE NONE CA No 90 85 88 82 99 111 97 107 96 104 95 100 94 98
45. 37216 45 56 160 M I II 14 EASY ABDUCT NONE NONE CA No 91 98 88 90 108 102 105 96 105 93 104 90 103 88
46. 36941 25 52 162 M I I 11 EASY ABDUCT NONE NONE CA No 86 92 84 90 94 112 92 108 91 104 90 101 88 98
47. 35296 45 60 165 M I I 13 EASY ABDUCT NONE NONE CA No 88 93 86 82 91 110 89 108 87 104 87 101 86 98
48. 35959 40 59 170 M I I 12 EASY ABDUCT NONE NONE CA No 82 100 80 84 90 108 88 106 86 108 86 99 85 96
49. 35050 31 62 160 M I I 14 EASY ABDUCT NONE NONE CA No 86 98 82 90 85 106 83 101 82 98 80 96 80 93
50. 34467 32 60 162 M I I 13 EASY ABDUCT NONE NONE CA No 90 96 89 91 87 111 85 106 84 102 84 98 84 95
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1. 39041 35 56 161 M I I 12 EASY ABDUCT NONE NONE CA No 85 98 87 98 100 120 90 112 98 109 97 104 95 103
2. 30416 28 51 151 F I I 14 EASY ABDUCT NONE NONE CA No 90 97 90 97 93 120 90 113 91 109 91 103 88 100
3. 34380 45 58 162 M I I 15 EASY ABDUCT NONE NONE CA No 85 98 84 90 90 115 90 112 88 108 86 105 84 100
4. 34950 28 59 164 M I I 17 difficult closed Coughing vigrous C-UA No 88 103 88 99 94 119 92 115 91 111 89 110 87 106
5. 34947 26 60 166 M I I 18 EASY ABDUCT Coughing NONE C-UA No 91 97 90 97 97 118 96 118 94 118 92 110 90 106
6. 35072 40 61 167 M I I 19 EASY ABDUCT NONE NONE CA No 90 97 90 97 99 119 97 117 93 111 91 109 90 105
7. 35577 30 59 165 M I I 17 difficult closed Coughing vigrous C-UA No 85 98 83 96 85 115 85 111 83 109 81 103 79 101
8. 35706 18 35 156 F II II 16 EASY ABDUCT NONE NONE CA No 100 90 91 89 93 111 93 106 90 103 88 97 86 95
9. 35705 30 45 152 F I I 16 EASY ABDUCT NONE NONE CA No 102 85 93 84 95 106 93 102 93 100 91 96 89 94
10. 33744 20 46 165 M I I 17 difficult closed Coughing vigrous C-UA No 96 97 90 96 100 113 98 110 97 108 95 103 93 100
11. 36976 30 56 166 M I I 15 difficult closed Coughing vigrous C-UA No 83 102 83 102 85 125 85 119 83 116 81 112 80 107
12. 35972 48 36 164 M I I 13 EASY ABDUCT NONE NONE CA No 88 98 86 92 92 115 92 110 88 106 87 103 86 99
13. 36769 29 41 153 F I II 12 EASY ABDUCT NONE NONE CA No 94 90 86 85 98 108 98 104 97 99 95 97 94 95
14. 40131 48 56 168 M I I 12 EASY ABDUCT Coughing NONE C-UA No 90 98 90 97 93 115 93 110 94 108 92 103 90 100
15. 36854 30 51 152 F I I 14 difficult closed Coughing vigrous C-UA yes 90 84 86 84 99 108 99 105 98 102 96 97 96 97
16. 37026 26 54 165 M I II 17 EASY ABDUCT NONE NONE CA No 91 102 91 94 96 114 96 111 94 109 92 102 90 98
17. 36857 35 50 167 M II I 13 EASY ABDUCT NONE NONE CA No 92 98 84 89 94 120 94 113 92 106 90 103 88 99
18. 39131 21 52 162 M I I 19 difficult closed Coughing vigrous C-UA yes 84 97 80 96 90 115 90 111 88 108 86 108 85 102
19. 37075 23 50 153 F I I 12 EASY ABDUCT NONE NONE CA No 88 97 88 96 93 116 92 112 91 106 89 104 87 98
20. 37471 23 54 167 M I I 15 EASY ABDUCT NONE NONE CA No 88 97 88 99 93 116 90 112 88 107 88 104 86 97
21. 57252 45 50 165 M I I 16 difficult closed Coughing vigrous C-UA yes 85 98 85 98 100 120 100 112 98 109 97 104 95 103
22. 36856 28 55 151 F I I 14 difficult closed Coughing vigrous C-UA No 90 97 90 97 93 120 93 113 91 109 91 103 88 100
23. 37650 50 56 164 M I I 15 EASY ABDUCT NONE NONE CA No 85 98 84 90 90 115 90 112 88 108 86 105 84 100
24. 37512 40 52 163 M I I 17 difficult closed Coughing vigrous C-UA yes 88 103 88 99 94 119 93 115 91 111 89 110 87 106
25. 37968 24 56 165 M II I 14 EASY ABDUCT Coughing NONE C-UA No 91 97 85 97 97 118 97 118 94 118 92 110 90 106
26. 38609 42 49 166 M I I 15 EASY ABDUCT NONE NONE CA No 90 97 90 97 99 119 99 117 93 111 91 109 90 105
27. 38757 46 54 167 M I I 18 difficult closed Coughing vigrous C-UA No 85 98 83 96 85 115 85 111 83 109 81 103 79 101
28. 38578 38 57 160 M I I 18 EASY ABDUCT NONE NONE CA No 100 90 91 89 93 111 93 106 90 103 88 97 86 95
29. 38581 45 50 164 M I I 12 EASY ABDUCT NONE NONE CA No 102 85 93 84 95 106 95 102 93 100 91 96 89 94
30. 44707 35 52 153 F I I 14 difficult closed Coughing vigrous C-UA No 96 97 96 96 100 113 99 110 97 108 95 103 93 100
31. 33077 47 65 161 M I I 12 EASY ABDUCT Coughing NONE C-UA No 85 98 85 98 100 120 100 112 98 109 97 104 95 103
32. 33766 37 51 151 M I I 14 difficult closed Coughing vigrous C-UA Yes 90 97 90 97 93 120 93 113 91 109 91 103 88 100
33. 35050 40 58 162 M I I 15 EASY ABDUCT NONE NONE CA No 85 98 84 90 90 115 90 112 88 108 86 105 84 100
34. 32981 33 59 164 F I I 17 difficult closed Coughing vigrous C-UA No 88 103 88 99 94 119 93 115 91 111 89 110 87 106
35. 33241 35 60 166 M I I 18 EASY ABDUCT NONE NONE CA No 91 97 91 97 97 118 97 118 94 118 92 110 90 106
36. 33090 35 51 167 F I I 19 EASY ABDUCT NONE NONE CA No 90 97 92 97 99 119 99 117 93 111 91 109 90 105
37. 33148 22 50 165 F I I 17 difficult closed Coughing vigrous C-UA No 85 98 83 96 85 115 85 111 83 109 81 103 79 101
38. 33060 38 35 156 M II I 16 EASY ABDUCT NONE NONE CA No 100 90 91 89 93 111 93 106 90 103 88 97 86 95
39. 31874 47 45 152 M I I 16 EASY ABDUCT NONE NONE CA No 102 85 93 84 95 106 95 102 93 100 91 96 89 94
40. 32722 20 46 165 M I I 17 difficult closed Coughing vigrous C-UA Yes 96 97 97 96 100 113 100 110 97 108 95 103 93 100
41. 33977 38 50 168 M I I 16 difficult closed Coughing vigrous C-UA No 85 98 87 98 100 120 100 112 98 109 97 104 95 103
42. 33966 47 52 162 M I I 14 EASY ABDUCT NONE NONE CA No 90 97 90 97 93 120 93 113 91 109 91 103 88 100
43. 34034 41 59 165 M I I 15 EASY ABDUCT NONE NONE CA No 85 98 84 90 90 115 90 112 88 108 86 105 84 100
44. 33423 26 62 167 M I I 17 difficult closed Coughing vigrous C-UA No 88 103 90 99 94 119 93 115 91 111 89 110 87 106
45. 33401 40 46 151 F II I 14 EASY ABDUCT NONE NONE CA No 91 97 95 97 97 118 98 118 94 118 92 110 90 106
46. 32700 34 58 156 M I I 15 EASY ABDUCT NONE NONE CA No 90 97 92 97 99 119 99 117 93 111 91 109 90 105
47. 32981 40 52 149 F I I 18 EASY ABDUCT NONE NONE CA No 85 98 83 96 85 115 85 111 83 109 81 103 79 101
48. 32241 40 52 165 M I I 18 difficult closed Coughing vigrous C-UA yes 100 90 91 89 93 111 93 106 90 103 88 97 86 95
49. 33090 25 46 148 F I I 12 EASY ABDUCT NONE NONE CA No 102 85 93 84 95 106 95 102 93 100 91 96 89 94
50. 33,148 35 48 150 F I I 14 EASY ABDUCT NONE NONE CA No 96 97 97 96 100 113 99 110 97 108 95 103 93 100
LARYNX ANATOMY
MUSCLES OF LARYNX
NERVE SUPPLY OF LARYNX
LARYNGEAL AXIS
MALLAM PATTI  CLASSIFICATION
CORMACK AND LEHANE GRADING OF
 LARYNGOSCOPIC VIEW




